...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >An open-label, 12-week clinical and sleep EEG study of nefazodone in chronic combat-related posttraumatic stress disorder.
【24h】

An open-label, 12-week clinical and sleep EEG study of nefazodone in chronic combat-related posttraumatic stress disorder.

机译：奈法唑酮在慢性战斗相关的创伤后应激障碍中的12周开放临床和睡眠EEG研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: We examined the effects of nefazodone on polysomnographic sleep measures and subjective reports of sleep quality and nightmares. as well as other symptoms, in patients with chronic combat-related posttraumatic stress disorder (PTSD) during a 12-week, open-label clinical trial. To our knowledge, this is the first polysomnographic study of treatment in patients with PTSD. METHOD: The subjects were 12 male veterans (mean age = 54 years) who met DSM-IV diagnostic criteria for PTSD (mean duration = 30 years). All but I patient also met DSM-IV criteria for major depressive disorder. Patients were evaluated weekly with clinical ratings in an open-label clinical trial. Polysomnographic recordings for 2 consecutive nights were obtained before treatment and at 2, 4, 8, and 12 weeks. The dose of nefazodone was adjusted according to individual clinical needs. Final mean daily dose was 441 mg. RESULTS: The patients reported significantly fewer nightmares and sleep problems during treatment. Nevertheless, contrary to studies in depressed patients, nefazodone did not significantly affect polysomnographic sleep measures compared with baseline. In addition, the patients showed significant improvement in the Clinical Global Impressions of PTSD symptoms (global score, hyperarousals and intrusions subscales), the Clinician-Administered PTSD Scale (global, hyperarousal, and intrusions subscales), the Hamilton Rating Scale for Depression (HAM-D). and the Beck Depression Inventory (BDI). CONCLUSION: These patients with chronic, treatment-resistant, combat-related PTSD showed significant improvement of subjective symptoms of nightmares and sleep disturbance, as well as depression and PTSD symptoms. in this 12-week open-label clinical trial. Nevertheless, objective polysomnographic sleep measures did not change. Further studies, including double-blind. placebo-controlled trials, are needed to extend these findings and to understand the relationships between the physiology of sleep and symptoms of poor sleep and nightmares.
机译：背景：我们研究了奈法唑酮对多导睡眠图睡眠指标的影响以及睡眠质量和噩梦的主观报告。在一项为期12周的开放标签临床试验中，对患有慢性战斗相关的创伤后应激障碍（PTSD）的患者进行了评估。据我们所知，这是对PTSD患者进行治疗的首项多导睡眠监测研究。方法：受试者为符合PTSD DSM-IV诊断标准（平均持续时间= 30年​​）的12名男性退伍军人（平均年龄= 54岁）。除我患者外，所有患者均符合重度抑郁症的DSM-IV标准。在开放标签的临床试验中，每周对患者进行临床评分评估。在治疗前和第2、4、8和12周连续2个晚上获得多导睡眠图记录。根据个人临床需要调整奈法唑酮的剂量。最终平均日剂量为441 mg。结果：患者报告在治疗期间噩梦和睡眠问题明显减少。然而，与抑郁症患者的研究相反，奈法唑酮与基线相比并未显着影响多导睡眠图睡眠指标。此外，患者在PTSD症状的临床总体印象（总体评分，超听觉和闯入子量表），临床医生管理的PTSD量表（全局，超听觉和闯入子量表），汉密尔顿抑郁量表（HAM）上显示出显着改善-D）。和贝克抑郁量表（BDI）。结论：这些患有慢性，抗药性，与战斗有关的创伤后应激障碍患者表现出恶梦和睡眠障碍的主观症状以及抑郁和创伤后应激障碍症状的显着改善。在这项为期12周的开放标签临床试验中。尽管如此，客观的多导睡眠监测睡眠指标并没有改变。进一步的研究，包括双盲。需要安慰剂对照试验来扩展这些发现，并了解睡眠生理与不良睡眠和噩梦症状之间的关系。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号